No Prescription |
 |
 | ||
|
Ziprax Suprax |
|
| ||
No Prescription » Prescription Drugs 17 » Ziprax Suprax Cefixime is a cephalosporin antibiotic used to treat infections caused by bacteria such as pneumonia; bronchitis; gonorrhea; and ear lung throat and urinary tract infections. Antibiotics will not work for colds flu or other viral infections. This antibiotic treats only bacterial infections. It will not work for viral infections (e.g. common cold flu). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.Cefixime comes as a tablet and liquid to take by mouth. It is usually taken once a day or every 12 hours (twice a day) for 5-14 days. Gonorrhea may be treated in 1-10 days. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take cefixime exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Buy Ziprax Suprax and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Ziprax Suprax: Product Type: Prescription Drugs 17 Ziprax ( Suprax Generic Cefixime ) Ziprax (Suprax Generic Cefixime) Suprax Generic Cefixime 100mg Suprax Generic Cefixime Ziprax
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
